CLL Society & Clinical Care Options created a ... - CLL Support

CLL Support

22,503 members38,652 posts

CLL Society & Clinical Care Options created a Patient Decision Support Tool

bkoffman profile image
bkoffmanCLL CURE Hero
5 Replies

The CLL Society + Clinical Care Options created this Clinical Care Options Interactive Decision Support Tool

! Check it out: clinicaloptions.com/Oncolog...

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
5 Replies
SethB34 profile image
SethB34

Man this is a really cool tool! I hope it gets around because it will really help.

Zia2 profile image
Zia2

So it’s only for those in treatment if I read the first question correctly.

debdetermine58 profile image
debdetermine58

THANK YOU!!!🤗bkoffman For this Awesome Interactive Tool !!! BRAVO !!! To the CLL SOCIETY & CLINICAL CARE!!!👏👏

gardening-girl profile image
gardening-girl

Dr. Koffman, I just tried using the Patient Decision Support Tool and was frustrated because the tool did not allow me to enter correct information due to the limited responses from which to choose.

-For example there were only 3 options for treatment settings: Newly diagnosed (first-line therapy), Second-line therapy or Third-line therapy. I'm in my 5th-line therapy.

-The choices for second-line therapy were limited to BTK inhibitor, Venetoclax-based therapy or PI3K inhibitor–based therapy. Again, no way for me to answer that question correctly. My second line therapy was FR.

-The choices for answering "Why did you discontinue your second-line treatment?" were limited to Intolerance or Progression. I discontinued second-line treatment after the scheduled 6 month treatment because I was in remission.

-There was no question asked about third-line therapy even though the following statement appears relative to treatment history, and one would think that providing information about third-line therapy (current according to the choices available) would be more important than info about the second-line therapy:

To quote: "Moreover, the specific agents used in previous therapy will be considered to help guide selection of subsequent therapy."

If that is truly important why are the choices limited to BTK inhibitor, Venetoclax-based therapy or PI3K inhibitor–based therapy? And, why was their no inquiry about what was being used in third-line therapy?

Considering that the tool might not be working properly using Safari, I tried using the tool with Firefox, but the format was identical.

There was no way to skip a question, so in my case incorrect information had to be entered in order to proceed to the specialist's recommendation. In my case I don't really need the tool, I was simply curious to see how it worked, and as I said, I found it to be very frustrating.

gardening-girl

bkoffman profile image
bkoffmanCLL CURE Hero

I will pass on your comments to the developers Thanks for the feedback and sorry about the frustrations.

You may also like...

Chemo-Free Treatment Best Option for CLL Patients Under 70

FCR. READ MORE: https://glennsabin.com/chemo-free-treatment-best-option-for-cll-patients-under-70/

Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL

000 patients from three German CLL Study Group clinical trials has identified that unfit patients...

Start Up Support Groups - CLL Society

starting monthly support groups. They say... “If you are looking to join a CLL Society support...

RICHTER'S TRANSFORMATION IN PATIENTS WITH CLL: ANALYSIS OF BIOLOGICAL AND CLINICAL RISK FACTORS AND OUTCOMES

TRANSFORMATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): ANALYSIS OF BIOLOGICAL AND...

Help the CLL Society find out what CLL patients & caregivers know and still \"yearn to learn\" about MRD testing + Limited Duration Therapies

CLL Society 2020 Patient Survey: Help the CLL Society find out what our CLL patients and their...